Core Insights - The company reported a significant increase in revenue and profit for the first half of 2025, with revenue reaching RMB 186 million, a year-on-year increase of 44.4% [1] - The gross profit rose to RMB 127 million, reflecting a 53.9% increase compared to the previous year [1] - The net profit attributable to shareholders was RMB 50.9 million, a substantial improvement from a net loss of RMB 5.1 million in the same period last year [1] Financial Performance - Revenue for the first half of 2025 was RMB 186 million, up 44.4% year-on-year [1] - Gross profit increased to RMB 127 million, with a gross margin of 68.2% [1] - The net profit attributable to shareholders was RMB 50.9 million, compared to a net loss of RMB 5.1 million in the previous year [1] Business Growth Drivers - The growth in revenue was primarily driven by increased sales of hemorrhagic stroke treatment devices and ischemic stroke treatment devices [1] - Sales of ischemic stroke treatment devices and other related devices rose by 38.3% and 29.2%, respectively [1] - The introduction of new devices contributed approximately RMB 37.7 million to revenue from hemorrhagic stroke treatment devices [1] Cost Management - The company achieved a reduction in overall expense ratios, with sales and distribution expenses and administrative expenses decreasing from 44.8% to 37.0% compared to the same period last year [1] Research and Development - The company invested RMB 20.6 million in R&D to support diverse projects for neuro-interventional treatment devices [2] - The blood flow-directed device has received NMPA approval, and a comprehensive solution for hemorrhagic stroke treatment devices has been launched and is now on sale [2] - Ongoing R&D includes self-expanding drug-eluting stents and carotid stents for treating intracranial stenosis [2] International Expansion - The company has obtained CE or FDA certification for its thrombectomy stents and other devices, with 31 registration certificates in eight other countries or regions [2] - Currently, the company is pursuing approximately 100 product registrations in 21 countries or regions to expand its sales channels [2]

Core Insights - The 2025 Oriental Cerebrovascular Disease Conference showcased the global launch of the Lattice NEXT, a new generation "headless" mechanical balloon mesh stent system by Aiko Medical, emphasizing innovation in neurointerventional solutions [2][4][18]. Group 1: Product Innovation - The Lattice NEXT stent has gained significant market share in a short time, receiving international acclaim for its innovative design and clinical applications [4][18]. - The stent's "headless" design enhances operational safety by reducing the risk of damage to branch vessels during procedures [11][18]. - The integration of a mechanical balloon with cobalt-chromium materials in the Lattice NEXT stent improves distal vascular compatibility and safety [7][12]. Group 2: Clinical Applications - Clinical data indicates that the Lattice series has been successfully applied to a wide range of cases, from routine to complex aneurysms, demonstrating superior performance in challenging scenarios [14][35]. - The stent's design allows for effective treatment of complex aneurysms, with a high follow-up cure rate observed in various clinical settings [7][35]. - The introduction of intelligent selection tools for stent sizing simplifies preoperative planning, particularly in complex anatomical cases [13][18]. Group 3: Expert Opinions - Experts have praised the Lattice NEXT for its design, which enhances intraoperative safety and provides more options for treating complex aneurysms [18][29]. - The mechanical balloon system has been highlighted for its ability to ensure proper stent placement even in tortuous vascular paths, showcasing its critical value in challenging cases [34][36]. - The collaborative development between R&D teams and clinical practitioners has been emphasized as a key factor in the rapid innovation and effectiveness of the Lattice products [15][29].